201 related articles for article (PubMed ID: 25411163)
1. Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of Pazopanib.
Maitland ML; Xu CF; Cheng YC; Kistner-Griffin E; Ryan KA; Karrison TG; Das S; Torgerson D; Gamazon ER; Thomeas V; Levine MR; Wilson PA; Bing N; Liu Y; Cardon LR; Pandite LN; O'Connell JR; Cox NJ; Mitchell BD; Ratain MJ; Shuldiner AR
Clin Cancer Res; 2015 Jan; 21(2):365-72. PubMed ID: 25411163
[TBL] [Abstract][Full Text] [Related]
2. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.
Xu CF; Bing NX; Ball HA; Rajagopalan D; Sternberg CN; Hutson TE; de Souza P; Xue ZG; McCann L; King KS; Ragone LJ; Whittaker JC; Spraggs CF; Cardon LR; Mooser VE; Pandite LN
J Clin Oncol; 2011 Jun; 29(18):2557-64. PubMed ID: 21576632
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma.
Apellániz-Ruiz M; Diekstra MH; Roldán JM; Boven E; Castellano D; Gelderblom H; Mathijssen RHJ; Swen JJ; Böhringer S; García-Donás J; Rini BI; Guchelaar HJ; Rodríguez-Antona C
Pharmacogenet Genomics; 2017 Jun; 27(6):227-231. PubMed ID: 28430711
[TBL] [Abstract][Full Text] [Related]
4. Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma.
Suttle AB; Ball HA; Molimard M; Hutson TE; Carpenter C; Rajagopalan D; Lin Y; Swann S; Amado R; Pandite L
Br J Cancer; 2014 Nov; 111(10):1909-16. PubMed ID: 25349968
[TBL] [Abstract][Full Text] [Related]
5. Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib.
Nikolinakos PG; Altorki N; Yankelevitz D; Tran HT; Yan S; Rajagopalan D; Bordogna W; Ottesen LH; Heymach JV
Cancer Res; 2010 Mar; 70(6):2171-9. PubMed ID: 20215520
[TBL] [Abstract][Full Text] [Related]
6. Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study.
Sleijfer S; Gorlia T; Lamers C; Burger H; Blay JY; Le Cesne A; Scurr M; Collin F; Pandite L; Marreaud S; Hohenberger P
Br J Cancer; 2012 Aug; 107(4):639-45. PubMed ID: 22805326
[TBL] [Abstract][Full Text] [Related]
7. Antitumor Response of VEGFR2- and VEGFR3-Amplified Angiosarcoma to Pazopanib.
Ravi V; Sanford EM; Wang WL; Ross JS; Ramesh N; Futreal A; Patel S; Stephens PJ; Miller VA; Ali SM
J Natl Compr Canc Netw; 2016 May; 14(5):499-502. PubMed ID: 27160228
[TBL] [Abstract][Full Text] [Related]
8. Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study.
Hamberg P; Boers-Sonderen MJ; van der Graaf WT; de Bruijn P; Suttle AB; Eskens FA; Verweij J; van Herpen CM; Sleijfer S
Br J Cancer; 2014 Feb; 110(4):888-93. PubMed ID: 24366297
[TBL] [Abstract][Full Text] [Related]
9. Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide.
O'Donnell PH; Karovic S; Karrison TG; Janisch L; Levine MR; Harris PJ; Polite BN; Cohen EE; Fleming GF; Ratain MJ; Maitland ML
Clin Cancer Res; 2015 Nov; 21(22):5092-9. PubMed ID: 26199386
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
Xie M; He CS; Huang JK; Lin QZ
Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.
Zivi A; Cerbone L; Recine F; Sternberg CN
Expert Opin Drug Saf; 2012 Sep; 11(5):851-9. PubMed ID: 22861374
[TBL] [Abstract][Full Text] [Related]
12. Pazopanib for the treatment of renal cancer.
Al-Marrawi MY; Rini B
Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
[TBL] [Abstract][Full Text] [Related]
13. [Pazopanib for treatment of renal cell carcinoma and soft tissue sarcomas].
Brotelle T; Bay JO
Bull Cancer; 2014 Jun; 101(6):641-6. PubMed ID: 24977453
[TBL] [Abstract][Full Text] [Related]
14. Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial.
Hainsworth JD; Rubin MS; Arrowsmith ER; Khatcheressian J; Crane EJ; Franco LA
Clin Genitourin Cancer; 2013 Sep; 11(3):270-5. PubMed ID: 23665131
[TBL] [Abstract][Full Text] [Related]
15. Pazopanib as third line therapy for metastatic renal cell carcinoma: clinical efficacy and temporal analysis of cytokine profile.
Pal SK; Hossain DM; Zhang Q; Frankel PH; Jones JO; Carmichael C; Ruel C; Lau C; Kortylewski M
J Urol; 2015 Apr; 193(4):1114-21. PubMed ID: 25286010
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review.
Boudou-Rouquette P; Tlemsani C; Blanchet B; Huillard O; Jouinot A; Arrondeau J; Thomas-Schoemann A; Vidal M; Alexandre J; Goldwasser F
Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1433-1444. PubMed ID: 27556889
[TBL] [Abstract][Full Text] [Related]
17. (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor.
Hamberg P; Verweij J; Sleijfer S
Oncologist; 2010; 15(6):539-47. PubMed ID: 20511320
[TBL] [Abstract][Full Text] [Related]
18. Pazopanib for the treatment of metastatic renal cell carcinoma.
Pick AM; Nystrom KK
Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
[TBL] [Abstract][Full Text] [Related]
19. Technical considerations in the development of circulating peptides as pharmacodynamic biomarkers for angiogenesis inhibitors.
Thomeas V; Chow S; Gutierrez JO; Karovic S; Wroblewski K; Kistner-Griffin E; Karrison TG; Maitland ML
J Clin Pharmacol; 2014 Jun; 54(6):682-7. PubMed ID: 24374901
[TBL] [Abstract][Full Text] [Related]
20. Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma.
Iacovelli R; Massari F; Albiges L; Loriot Y; Massard C; Fizazi K; Escudier B
Eur Urol; 2015 Jul; 68(1):154-60. PubMed ID: 25466943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
